Live Webinar

Delivering Cellular Therapy in Community Oncology: OHC’s Approach

Presented by The Community Oncology Alliance

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
|Articles|June 21, 2021

Evidence-Based Oncology

  • June 2021
  • Volume 27
  • Issue 4

Weidner et al, Appendices

Appendices to: Observations Regarding the Average Sales Price Reimbursement Methodology

eAPPENDICES Weidner et al

Articles in this issue

over 5 years ago

Dollars and Sense

over 5 years ago

FDA Panel Votes to Keep 4 of 6 “Dangling Approvals,” in a Sign of Things to Come

over 5 years ago

Observations Regarding the Average Sales Price Reimbursement Methodology

over 5 years ago

Real-World Evidence Is Key to Accelerating Oncology Approvals

over 5 years ago

PATHWAYS: Oncology Care Pathways Launched by Payers: What Are the Trends?

over 5 years ago

Biosimilars Drive Savings in Medicare’s Oncology Care Model

over 5 years ago

A Social Worker Leads ACCC, and Her Timing Is Perfect

over 5 years ago

After PD-1 Inhibitor Indications Are Withdrawn in SCLC, What Now?

Related to this article

View more